Mike Pinder.
ALISO VIEJO, Calif.—SpyGlass Pharma, Inc. (Nasdaq: SGP), a late-stage biopharmaceutical company focused on transforming treatment paradigms for patients with chronic eye conditions, has announced the appointment of Mike Pinder as vice president, marketing, effective May 18, 2026. Pinder brings more than 20 years of commercial launch experience in ophthalmology, focused on building, launching and evolving brands, notably in the buy-and-bill specialty pharma model, the announcement said. In the newly created role, SpyGlass Pharma said he will build and lead the company’s marketing function as it continues to progress the Bimatoprost Drug Pad-IOL System (BIM-IOL System) through phase 3 clinical trials and toward potential commercialization upon U.S. Food and Drug Administration (FDA) approval.
“We are thrilled to welcome Mike to SpyGlass Pharma as we continue to enroll participants into our two BIM-IOL System phase 3 trials,” said Patrick Mooney, chief executive officer of SpyGlass Pharma. “Mike’s deep experience in building successful ophthalmology brands across buy-and-bill specialty pharma and medical device products will augment our plans for a successful BIM-IOL launch.”
In making the announcement, SpyGlass said Pinder has a proven track record of building and launching significant ophthalmology brands with award-winning campaigns. He was most recently head of marketing for Izervay—a prescription eye injection specifically designed to slow the progression of geographic atrophy—at Astellas Pharma. Prior to launching Izervay, Pinder led patient marketing in the Novartis ophthalmology buy-and-bill retina franchise and hospital marketing at Johnson & Johnson, cultivating ophthalmology marketing launch experiences across a range of brands. Prior to these roles, Pinder held positions in payer marketing and sales leadership at Johnson & Johnson. He earned a bachelor of arts degree in communications from the University of Massachusetts Amherst.
“I am thrilled to join SpyGlass Pharma and help advance the company’s mission to give patients vision that endures with drug delivery that lasts,” said Pinder. “The BIM-IOL System is a first-and-only product: the 2-for-1 vision solution and the glaucoma sustained drug delivery option that every single cataract surgeon can do. I look forward to the potential of bringing this technology to a community desperately in need of more drop-free alternatives to glaucoma management.”
